Scienture Holdings, Inc. formalized a commercial PBM-led GPO rebate agreement for Arbli oral suspension, advancing formulary access with health plans covering over 100 million lives. Discussions are ongoing to expand commercial and government coverage for the product. Arbli is FDA-approved for hypertension and diabetic nephropathy treatment.

Arbli is the first FDA-approved, ready-to-use oral liquid losartan in the U.S. market, eliminating the need for compounding with reduced dosing volume and long-term shelf life at room temperature. The U.S. losartan market represents approximately $256 million in annual sales with all currently marketed products in oral solid form, according to IQVIA data.

In August, Scienture announced a registered direct offering of 3.225 million shares at $1.20 per share, generating approximately $3.9 million in gross proceeds. SCNX stock was down 4.01% at $0.94 during the premarket session. The company aims to position Arbli for rapid adoption in the US market with the new rebate agreement.

Read more at Yahoo Finance: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market